Publication: Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder
Date
Authors
Authors
Köle, İsmail Hasan
Vural, Pınar
Yurdacan, Beste
Alemdar, Adem
Mutlu, Caner
Advisor
Language
Type
Publisher:
Springer Heidelberg
Journal Title
Journal ISSN
Volume Title
Abstract
Background There is insufficient replicated data to establish a relationship between the polymorphisms of SLC6A2 and CYP2D6 and the treatment responses of atomoxetine (ATX) in ADHD. We focused on evaluating the effect of top-line single nucleotide polymorphisms (SNPs) in SLC6A2 and CYP2D6 on the ATX treatment response in attention deficit and hyperactivity disorder (ADHD). Methods Of 160 patient records, 34 patients who met the inclusion criteria were evaluated to determine the relationship between genotypes of ten SNPs (six of SLC6A2 and four of CYP2D6) and ATX treatment response. Additionally, the connection between SNPs of CYP2D6 and the severity of side effects associated with ATX was analyzed in 37 patients, including the 34 study patients, and three patients discontinued because of ATX-dependent side effects. Results All six polymorphisms we studied in SLC6A2 were associated with the treatment response of ATX. Clinical improvement in oppositional defiant disorder symptoms of patients with ADHD was only observed in carriers of the homozygous "C" allele of rs3785143 (p(odd) = 0.026). We detected an association between higher CGI-side-effect severity scores and the "TT" genotype of rs1065852 polymorphism in CYP2D6 (p = 0.043). Conclusions The findings of this study suggest that genotypes of polymorphisms within the SLC6A2 and CYP2D6 may play an influential role in treatment response or the severity of side effects associated with ATX in ADHD patients.
Description
Source:
Keywords:
Keywords
Norepinephrine transporter gene, Deficit/hyperactivity disorder, Methylphenidate response, Clinical-response, Children, Association, Adolescents, Variants, Atomoxetine, Attention deficit and hyperactivity disorder, Genetic polymorphism, CYP2D6 , Genetic polymorphism, SLC6A2, Pharmacology & pharmacy